** Shares of cancer drug developer iTeos Therapeutics ITOS.O rise 4.5% to $7.15 in the afternoon trade
** Company reports Q4 net loss of $1.01 per share, compared to analysts' estimates of a loss of $1.06 per share, according to data compiled by LSEG
** ITOS expects its cash balance of $655 million to provide a runway through 2027
** ITOS down 38.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.